News, Publications & Presentations 

Data from an ongoing collaboration between Immodulon Therapeutics and the laboratory of Prof. Andrew MacDonald at Manchester Collaborative Centre for Inflammation Research (University of Manchester, Manchester UK) on the effects of combination treatment of IMM‑101 (a...

It is with great sadness that Immodulon announces the passing of Professor John Grange, one of the founding members of Immodulon. John played a crucial role in establishing the company for which the entire Immodulon team will always be extremely grateful. His death is...

In IMAGE-1, a phase II proof-of-concept study recruiting 110 patients with locally advanced or metastatic pancreatic cancer, patients were randomized to receive IMM‑101 + gemcitabine or gemcitabine alone. This study was designed to provide indicative rather than...

Further data from an ongoing collaboration between the laboratory of Prof. Andrew MacDonald at Manchester Collaborative Centre for Inflammation Research (University of Manchester, Manchester, UK) and Immodulon Therapeutics on the effects of IMM-101 (a heat-killed...

Results from pre-clinical research conducted at the University of Colorado Boulder in the USA led by Dr Chris Lowry, as part of an agreement with Immodulon to test Mycobacterium vaccae NCTC11659 in a variety of laboratory models of mental health disorders. Full title:...

In this review, Immodulon in collaboration with Myriad Rule Based Medicine (USA) describes the TruCulture® system. This technology applied to small whole blood sample permits investigation of immunological activity following immune stimulation resulting in synthesis...

A collaboration between the laboratory of Prof. Andrew MacDonald at Manchester Collaborative Centre for Inflammation Research (University of Manchester, Manchester, UK) and Immodulon Therapeutics investigating the effects of IMM-101 (a heat-killed whole cell...

A collaboration between the laboratory of Prof. George Bahr at the University of Balamand, Lebanon and Immodulon Therapeutics investigating the effects of IMM‑101 (a heat-killed whole cell preparation of Mycobacterium obuense NCTC13365) on various cells of the immune...

In this review, Immodulon along with clinical collaborators gives an overview of new immune-related therapeutic strategies currently being tested in clinical trials in metastatic pancreatic cancer. This paper proposes that immunotherapeutic strategies in combination...

An Open Label Long‑term Follow‑up Study for Patients with Melanoma who were previously Enrolled in the Phase I Study IMM‑101‑001Phase I EudraCT No. 2011-003967-31 ClinicalTrials.gov NCT01559818 Following the completion of study IMM‑101‑001, patients were given the...

LONDON, UK – Thursday 23 July, 2015 – Immodulon Therapeutics, a privately held, late-stage biopharmaceutical company focused on immuno-oncology, has made a new senior appointment to its Board ofDirectors to support its continued growth and development. Dr James...

LONDON, UK – Wednesday 10 June, 2015 – Immodulon Therapeutics, a privately held, late-stage biopharmaceutical company focused on immuno-oncology, has made two new senior appointments to its Board of Directors to support its continued growth. Anthony Bolton, one of the...

LONDON, UK – December 16, 2014 - Immodulon Therapeutics today announced that Orphan designation EU/3/14/1385 was granted by the European Commission for IMM-101, heat-killed Mycobacterium obuense (whole cell) for the treatment of pancreatic...

Collaborations between Immodulon Therapeutics and academic laboratories in London Universities are yielding new data showing promising therapeutic effects of treatment with IMM-101 (a heat-killed whole cell preparation of Mycobacterium obuense...

LONDON, UK – September 23, 2014 - Immodulon Therapeutics today announced that Orphan designation was granted by the FDA for IMM-101, heat-killed Mycobacterium obuense (whole cell) for the treatment of pancreatic cancer.

Pancreatic cancer is an aggressive cancer with poor prognosis. Despite its low incidence, it is the 4th cause of cancer-related death in the US. Journal: Journal of ImmunoTherapy of Cancer Author[s]: Androulla Elia, Louise Lincoln, Laura Rosa...

In this review, Immodulon along with academic collaborators charts the history of use of bacterial preparations, including mycobacterial products, as immunotherapeutic agents for the treatment of cancer and present evidence to explain the potential value of this...

A Phase II, Single Arm, Investigative Study of IMM‑101 in Combination with Radiation Induced Tumour Necrosis in Patients with Previously Treated Colorectal Cancer Exploratory Phase II EudraCT No. 2011-003958-85 ClinicalTrials.gov NCT01539824 In June 2012, a Phase II,...

Journal: Cancer Immunology, Immunotherapy Author[s]: Daniel W. Fowler, John Copier, Natalie Wilson, Angus G. Dalgleish, Mark D. Bodman-Smith This work was in collaboration with St George's Hospital, London DOI: 10.1007/s00262-011-1121-4 Date: 15 October 2011

IMM-101 is a heat-killed innate and adaptive immune-activating mycobacterial product; a phase I study aimed to determine its safety and tolerability in individuals with melanoma Journal: Annals of Oncology Author[s]: J. Stebbing, A. Dalgleish,...